Lynparza (olaparib) - Merck (MSD), AstraZeneca
Lynparza: Expiry of patents in US in 2028, between 2022- 2024 and 2024- 2031 (AstraZeneca) - Mar 21, 2020 - Annual Report 2019: Expiry of patents in China between 2021- 2024 and 2024- 2029; Expiry of patents in EU between 2021- 2029 and between 2024- 2029; Expiry of patents in Japan between 2021- 2029 and 2024- 2033 
Patent
https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2019/pdf/AstraZeneca_AR_2019.pdf
 
Mar 21, 2020
 
 
a3d0f5c9-2836-4356-83c5-279ed9e8122b.jpg